Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid
(Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in
subjects with advanced cancer and multiple myeloma (excluding breast and prostate cancer)